Sequence 5 from Patent US 20110319336

General Information


DRACP ID  DRACP01382

Peptide Name   Sequence 5 from Patent US 20110319336

Sequence  MQLPLAT

Sequence Length  7

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic construct

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01382

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C34H60N8O10S

Absent amino acids  CDEFGHIKNRSVWY

Common amino acids  L

Mass  88017

Pl  6.11

Basic residues  0

Acidic residues  0

Hydrophobic residues  3

Net charge  0

Boman Index  589

Hydrophobicity  78.57

Aliphatic Index  125.71

Half Life 
  Mammalian: 30 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  1

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2011/0319336 A1

Patent Title  Selective anticancer chimeric peptide.

Other Iinformation  Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status: Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013

Other Published ID  CN102238965A  EP2370107A2  WO2010064207A2  WO2010064207A3 




DRACP is developed by Dr.Zheng's team.